复方斑蝥胶囊联合内分泌治疗、化疗对晚期乳腺癌的影响

Effect of Compound Banmao Capsule Combined with Endocrinetherapy and Chemotherapy on Adranced Breast Cancer

目的:评估复方斑蝥胶囊在晚期乳腺癌治疗中的疗效。方法:选择2010年1月-2013年5月在我科治疗的晚期乳腺癌患者共70例,采用随机对照方法,分为单纯内分泌药物治疗组(简称内分泌组)13例、内分泌药物+复方斑蝥胶囊组(简称内分泌结合组)13例;单纯化疗组(简称化疗组)22例、化疗+复方斑蝥胶囊组(简称化疗结合组)22例,分别比较单纯内分泌药物或化疗治疗组与联合复方斑蝥胶囊治疗组的缓解率、疾病进展时间、生存期、生活质量及不良反应。结果:联合组较单纯组中位疾病进展时间明显延长(P<0.05);联合组和单纯组在缓解率及不良反应方面差异无显著性。结论:复方斑蝥胶囊能延长疾病进展时间,与化疗或内分泌药物共同用于治疗晚期转移性乳腺癌值得临床推广应用。

Objective： To evaluate Compound Banmao capsule in the treatment of advanced breast cancer. Methods： Using ran- domized controlled method, a total of 70 patients with advanced breast cancer treated in our department from January 2010 to May 2013 are diveded into g groups：13 cases with pure endocrine therapy （hereinafter referred to as Group E）; 13 cases with endocrine drug combined with Compound Banmao capsule （Group E＋BM） ; 22 cases with pure chemotherapy （Group CH） and 22 cases with chemotherapy combined with Compound Banmao capsule （Group CH＋BM）. Aspects of remission rate, progression of disease, survival time, quality of life and adverse reaction are compared respectively between Group E/Group CH and Group E＋BM/Group CH＋BM. Results： The median time of disease progression of Group E＋BM and Group CH＋BM is obviously longer than Group E and Group CH （P 〈 0.05）;There＇re no significant differences between Group E/Group CH and Group E＋BM/Group CH＋BM in remission rate and adverse reaction. Conclusions： Compound cantharis capsule（Compound Banmao capsule ） can extend the time of disease progression, and it is worth clinical application when used together with chemotherapy or endocrine drugs treatment of advanced metastatic breast cancer.